德国拜耳生产的抗凝药拜瑞妥在国内上市了吗？

In recent years, new anticoagulant drugs Factor Xa (FXa) inhibitors have received more and more attention among anticoagulant drugs, among which Bayer of Germany is the representative drug of FXa inhibitors. Xarelto is a small molecule oral anticoagulant. Xarelto is an oxazolidinone-derived selective FXa inhibitor that acts on the active site of factor

Headquartered in Leverkusen, Germany, Bayer has 750 production plants in 200 locations on six continents; it has 120,000 employees and 350 branches in almost every country in the world. Polymers, medicine and health care, chemical industry and agriculture are the company's four pillar industries.

Xarelto is suitable for:

1. Adult patients undergoing elective hip or knee replacement surgery to prevent venous thrombosis (VTE).

2. Treat venous thrombosis (DVT) in adults and reduce the risk of DVT recurrence and pulmonary embolism (PE) after acute DVT.

3. Adult patients with nonvalvular atrial fibrillation who have one or more risk factors (e.g., congestive heart failure, hypertension, age ≥75 years, diabetes, history of stroke or transient ischemic attack) to reduce the risk of stroke and systemic embolism.

There are limited data on the relative effectiveness of Xarelto compared with warfarin in reducing the risk of stroke and systemic embolism in conditions well controlled with warfarin therapy.

So has the anticoagulant drug Xarelto produced by Bayer in Germany been launched in China?

It is understood that it has been launched in China in 2009. Since the domestic price is not suitable for patients to take it for a long time, most patients use the foreign version!

Recommended related hot articles: /newsDetail/88196.html